Interview with Head of Department of Experimental Cancer Jon Amund Kyte by Pharma Boardroom 

Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer treatment in the country are.


BM7PE - New study for colorectal cancer open for inclusion at OUS, Radiumhospitalet

A phase I/II study with BM7PE immunotoxin in colorectal cancer patients with metastactic  disease who are refractory to or with intolerance to last line of standard chemotherapy.